Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0U0SK
|
|||
| Former ID |
DIB008415
|
|||
| Drug Name |
GZ402668
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Multiple sclerosis [ICD-11: 8A40; ICD-9: 340] | Phase 1 | [1] | |
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Cambridge pathology 1 antigen (CD52) | Target Info | . | [2], [3] |
| NetPath Pathway | IL2 Signaling Pathway | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT02282826) A First-in-human, Single Ascending Dose Study of GZ402668 in Patients With Progressive Multiple Sclerosis. U.S. National Institutes of Health. | |||
| REF 2 | Characterization of a Next Generation Anti-CD52 Antibody. Neurology. April 6, 2015 vol. 84 no. 14. | |||
| REF 3 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.